Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of novel endocrine therapy for prostate cancer and adrenocortical function
ChiCTR2300068049Phase 4Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jan 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of abiraterone, apalutamide, darolutamide and enzalutamide in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by Beijing An Zhen Hospital. Primary endpoints: Plasma cortisol, ACTH and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
abirateroneapalutamidedarolutamideenzalutamide
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2300068049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068049.